{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:45:58Z","timestamp":1788403558446,"version":"build-2803163510"},"reference-count":36,"publisher":"Society of Nuclear Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.2967\/jnumed.114.149062","type":"journal-article","created":{"date-parts":[[2015,2,27]],"date-time":"2015-02-27T02:48:15Z","timestamp":1425005295000},"page":"628-634","source":"Crossref","is-referenced-by-count":34,"title":["Preclinical Evaluation of <sup>86<\/sup>Y-Labeled Inhibitors of Prostate-Specific Membrane Antigen for Dosimetry Estimates"],"prefix":"10.2967","volume":"56","author":[{"given":"Sangeeta Ray","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine A.","family":"Foss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrudula","family":"Pullambhatla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthamizhchelvan","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwamena E.","family":"Baidoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin W.","family":"Brechbiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar","family":"Nimmagadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie C.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Sgouros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin G.","family":"Pomper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2015,2,26]]},"reference":[{"key":"2021051712073125000_56.4.628.1","doi-asserted-by":"publisher","DOI":"10.2174\/157340611796799249"},{"key":"2021051712073125000_56.4.628.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2005.06.007"},{"key":"2021051712073125000_56.4.628.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.043"},{"key":"2021051712073125000_56.4.628.4","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1007\/s00259-004-1571-4","article-title":"Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours","volume":"31","author":"Bodei","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021051712073125000_56.4.628.5","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1007\/s00259-004-1561-6","article-title":"Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours","volume":"31","author":"Helisch","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021051712073125000_56.4.628.6","first-page":"1148","article-title":"Pharmacokinetics and biodistribution of 86Y-trastuzumab for 90Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI","volume":"44","author":"Palm","year":"2003","journal-title":"J Nucl Med."},{"key":"2021051712073125000_56.4.628.7","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.10661"},{"key":"2021051712073125000_56.4.628.8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.8097"},{"key":"2021051712073125000_56.4.628.9","doi-asserted-by":"publisher","DOI":"10.2174\/157488707781662724"},{"key":"2021051712073125000_56.4.628.10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1735443100"},{"key":"2021051712073125000_56.4.628.11","doi-asserted-by":"publisher","DOI":"10.2174\/1568026611313080008"},{"key":"2021051712073125000_56.4.628.12","doi-asserted-by":"publisher","DOI":"10.1021\/jm100623e"},{"key":"2021051712073125000_56.4.628.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.104661"},{"key":"2021051712073125000_56.4.628.14","unstructured":"Kulkarni H Weineisen M Mueller D . First clinical results with Lu-177 PSMA-TUM1 for the treatment of castrate-resistant metastatic prostate cancer. J Nucl Med. 2014;55(suppl 1):10."},{"key":"2021051712073125000_56.4.628.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2713-y"},{"key":"2021051712073125000_56.4.628.16","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.18632\/oncotarget.415","article-title":"A modular strategy to prepare multivalent inhibitors of prostate-specific membrane antigen (PSMA)","volume":"2","author":"Banerjee","year":"2011","journal-title":"Oncotarget."},{"key":"2021051712073125000_56.4.628.17","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201102872"},{"key":"2021051712073125000_56.4.628.18","doi-asserted-by":"publisher","DOI":"10.1021\/jm800111u"},{"key":"2021051712073125000_56.4.628.19","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.7.6.5968"},{"key":"2021051712073125000_56.4.628.20","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-011-2039-y"},{"key":"2021051712073125000_56.4.628.21","doi-asserted-by":"publisher","DOI":"10.1021\/nn301725w"},{"key":"2021051712073125000_56.4.628.22","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(73)90196-2"},{"key":"2021051712073125000_56.4.628.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2004.02358.x"},{"key":"2021051712073125000_56.4.628.24","doi-asserted-by":"publisher","DOI":"10.1088\/0031-9155\/56\/3\/012"},{"key":"2021051712073125000_56.4.628.25","first-page":"958","article-title":"Letter: expression of tissue isotope distribution","volume":"16","author":"Woodard","year":"1975","journal-title":"J Nucl Med."},{"key":"2021051712073125000_56.4.628.26","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.056036"},{"key":"2021051712073125000_56.4.628.27","first-page":"1023","article-title":"OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine","volume":"46","author":"Stabin","year":"2005","journal-title":"J Nucl Med."},{"key":"2021051712073125000_56.4.628.28","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin Cancer Res."},{"key":"2021051712073125000_56.4.628.29","doi-asserted-by":"publisher","DOI":"10.1118\/1.4752213"},{"key":"2021051712073125000_56.4.628.30","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.109.066738"},{"key":"2021051712073125000_56.4.628.31","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402320"},{"key":"2021051712073125000_56.4.628.32","doi-asserted-by":"publisher","DOI":"10.3390\/ph7050517"},{"key":"2021051712073125000_56.4.628.33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.160"},{"key":"2021051712073125000_56.4.628.34","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3389\/fonc.2013.00214","article-title":"Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancer","volume":"3","author":"Tagawa","year":"2013","journal-title":"Front Oncol."},{"key":"2021051712073125000_56.4.628.35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0231"},{"key":"2021051712073125000_56.4.628.36","first-page":"634","article-title":"Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?","volume":"46","author":"Vallabhajosula","year":"2005","journal-title":"J Nucl Med."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.114.149062","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T20:00:37Z","timestamp":1621281637000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.114.149062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,26]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,4,1]]},"published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.2967\/jnumed.114.149062"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.114.149062","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,26]]}}}